Breaking news

Novel Biomedical (6810) product DNlite-IVD103 detection reagent, Thailand application name: DNlite-KT uPTM-FetA ELISA Kit (used to assess the risk of prognostic renal function failure in kidney transplant patients), has been issued an IVD listing license by the Thai competent authority . (The stock price was 39.9 yuan on November 8)

Novel Biomedical (6810) product DNlite-IVD103 detection reagent, Thailand application name: DNlite-KT uPTM-FetA ELISA Kit (used to assess the risk of prognostic renal function failure in kidney transplant patients), has been issued an IVD listing license by the Thai competent authority . (The stock price was 39.9 yuan on November 8)
Novel Biomedical (6810) product DNlite-IVD103 detection reagent, Thailand application name: DNlite-KT uPTM-FetA ELISA Kit (used to assess the risk of prognostic renal function failure in kidney transplant patients), has been issued an IVD listing license by the Thai competent authority . (The stock price was 39.9 yuan on November 8)
--

Novel Biomedical (6810) product DNlite-IVD103 detection reagent, Thailand application name: DNlite-KT uPTM-FetA ELISA Kit (used to assess the risk of prognostic renal function failure in kidney transplant patients), has been issued an IVD listing license by the Thai competent authority . (The stock price was 39.9 yuan on November 8)


Date: 2023/11/8
Author: Genet

Serial number 3 Speech date 112/11/08 Speech time 16:05:24
Spokesperson Guo Zuxun Spokesperson Title Financial Accounting Supervisor Spokesperson Tel: (03)560-1816
Purpose:Our company’s product DNlite-IVD103 detection reagent, Thailand’s application name: DNlite-KT uPTM-FetA ELISA Kit (used to assess the risk of prognostic renal failure in kidney transplant patients), has been issued an IVD listing license by the Thai competent authority.
Comply with Clause 44 of the Articles. Date of occurrence: 112/11/08

instruction
1. Date of occurrence: 112/11/08
2. Company name: Novel Biomedical Co., Ltd.
3. Relationship with the company (please enter the company or subsidiary): our company
4. Mutual shareholding ratio: Not applicable
5. Cause of occurrence: Our company received a notification today: The DNlite-IVD103 detection reagent applied in Thailand, with the application name DNlite-KT uPTM-FetA ELISA Kit, is used to assess the risk of prognostic renal failure in kidney transplant patients and has been approved by the Thai competent authority. (Thai Food and Drug Administration, Ministry of Public Heath) issues an IVD marketing license.
6. Countermeasures: None
7. Other matters that should be stated (if the main system where the event occurs or the resolution is a company with a public offering or above, the material information in this article also complies with the matters that have a significant impact on shareholders’ rights or securities prices as stipulated in Article 7, Paragraph 9 of the Enforcement Rules of the Securities and Exchange Act) ):
(1) Obtaining a Thai listing license will be beneficial to the local sales of our company’s products.
(2) The company belongs to the biotechnology industry. Regarding the company’s financial and revenue information, please refer to the public observatory data. Investors are advised to exercise prudent judgment and invest cautiously.

The article is in Chinese

Tags: Biomedical product DNliteIVD103 detection reagent Thailand application DNliteKT uPTMFetA ELISA Kit assess risk prognostic renal function failure kidney transplant patients issued IVD listing license Thai competent authority stock price yuan November

-

PREV The earlier you develop cardiovascular disease, the higher your risk of dementia | TechNews Technology News
NEXT Wash your hands frequently to prevent hand, foot and mouth disease | am730